262 related articles for article (PubMed ID: 29487310)
1. Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy.
Sougawa N; Miyagawa S; Fukushima S; Kawamura A; Yokoyama J; Ito E; Harada A; Okimoto K; Mochizuki-Oda N; Saito A; Sawa Y
Sci Rep; 2018 Feb; 8(1):3726. PubMed ID: 29487310
[TBL] [Abstract][Full Text] [Related]
2. Treating iPSC-Derived β Cells with an Anti-CD30 Antibody-Drug Conjugate Eliminates the Risk of Teratoma Development upon Transplantation.
Pellegrini S; Zamarian V; Landi E; Cospito A; Lombardo MT; Manenti F; Citro A; Schiavo Lena M; Piemonti L; Sordi V
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077097
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
[TBL] [Abstract][Full Text] [Related]
4. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.
Blatt K; Cerny-Reiterer S; Schwaab J; Sotlar K; Eisenwort G; Stefanzl G; Hoermann G; Mayerhofer M; Schneeweiss M; Knapp S; Rülicke T; Hadzijusufovic E; Bauer K; Smiljkovic D; Willmann M; Reiter A; Horny HP; Valent P
Blood; 2015 Dec; 126(26):2832-41. PubMed ID: 26486787
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.
Hasanali ZS; Epner EM; Feith DJ; Loughran TP; Sample CE
Mol Cancer Ther; 2014 Dec; 13(12):2784-92. PubMed ID: 25319394
[TBL] [Abstract][Full Text] [Related]
7. Ethanol extract of Magnoliae cortex (EEMC) limits teratoma formation of pluripotent stem cells by selective elimination of undifferentiated cells through the p53-dependent mitochondrial apoptotic pathway.
Kim A; Lee SY; Seo CS; Chung SK
Phytomedicine; 2020 Apr; 69():153198. PubMed ID: 32151917
[TBL] [Abstract][Full Text] [Related]
8. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR
Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199
[TBL] [Abstract][Full Text] [Related]
9. The tumourigenicity of iPS cells and their differentiated derivates.
Liu Z; Tang Y; Lü S; Zhou J; Du Z; Duan C; Li Z; Wang C
J Cell Mol Med; 2013 Jun; 17(6):782-91. PubMed ID: 23711115
[TBL] [Abstract][Full Text] [Related]
10. IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
Bauer K; Hadzijusufovic E; Cerny-Reiterer S; Hoermann G; Reifinger M; Pirker A; Valent P; Willmann M
Vet Comp Oncol; 2017 Dec; 15(4):1240-1256. PubMed ID: 27507155
[TBL] [Abstract][Full Text] [Related]
11. Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.
Griscelli F; Féraud O; Oudrhiri N; Gobbo E; Casal I; Chomel JC; Biéche I; Duvillard P; Opolon P; Turhan AG; Bennaceur-Griscelli A
Am J Pathol; 2012 May; 180(5):2084-96. PubMed ID: 22425713
[TBL] [Abstract][Full Text] [Related]
12. An Ethanol Extract of
Kim A; Baek SJ; Shin S; Lee SY; Chung SK
Nutrients; 2023 May; 15(10):. PubMed ID: 37242247
[TBL] [Abstract][Full Text] [Related]
13. CD30: from basic research to cancer therapy.
Muta H; Podack ER
Immunol Res; 2013 Dec; 57(1-3):151-8. PubMed ID: 24233555
[TBL] [Abstract][Full Text] [Related]
14. Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes.
Takeda M; Ito E; Minami K; Harada A; Mochizuki-Oda N; Sawa Y; Miyagawa S
Biochem Biophys Res Commun; 2021 Oct; 574():91-96. PubMed ID: 34450429
[TBL] [Abstract][Full Text] [Related]
15. Efficient, Selective Removal of Human Pluripotent Stem Cells via Ecto-Alkaline Phosphatase-Mediated Aggregation of Synthetic Peptides.
Kuang Y; Miki K; Parr CJC; Hayashi K; Takei I; Li J; Iwasaki M; Nakagawa M; Yoshida Y; Saito H
Cell Chem Biol; 2017 Jun; 24(6):685-694.e4. PubMed ID: 28529132
[TBL] [Abstract][Full Text] [Related]
16. CD30 Receptor-Targeted Lentiviral Vectors for Human Induced Pluripotent Stem Cell-Specific Gene Modification.
Friedel T; Jung-Klawitter S; Sebe A; Schenk F; Modlich U; Ivics Z; Schumann GG; Buchholz CJ; Schneider IC
Stem Cells Dev; 2016 May; 25(9):729-39. PubMed ID: 26956718
[TBL] [Abstract][Full Text] [Related]
17. Prunellae Spica Extract Suppresses Teratoma Formation of Pluripotent Stem Cells through p53-Mediated Apoptosis.
Kim A; Lee SY; Seo CS; Chung SK
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32182802
[TBL] [Abstract][Full Text] [Related]
18. CD30 is a potential therapeutic target in malignant mesothelioma.
Dabir S; Kresak A; Yang M; Fu P; Wildey G; Dowlati A
Mol Cancer Ther; 2015 Mar; 14(3):740-6. PubMed ID: 25589494
[TBL] [Abstract][Full Text] [Related]
19. Elimination of Teratogenic Human Induced Pluripotent Stem Cells by Bee Venom via Calcium-Calpain Pathway.
Kim A; Lee SY; Kim BY; Chung SK
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380745
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
